Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: Analyses with the RAMQ database

BMC Gastroenterology

Volumn 13, Issue 1, 2013, Pages

  Lachaine, Jean ^a   Yen, Linnette ^b   Beauchemin, Catherine ^a   Hodgkins, Paul ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b SHIRE   (United States)

Author keywords

Adherence; Anti inflammatory drugs; Persistence; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; MESALAZINE;

ADULT; AGE DISTRIBUTION; AGED; ANALYTICAL PARAMETERS; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED DRUG RELEASE; DELAYED DRUG RELEASE; DISEASE SEVERITY; EXTENDED DRUG RELEASE; FACTUAL DATABASE; FEMALE; HEALTH INSURANCE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICATION POSSESSION RATIO; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SELECTION; PRESCRIPTION; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; SEX DIFFERENCE; TABLET; TREATMENT DURATION; ULCERATIVE COLITIS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CANADA; COLITIS, ULCERATIVE; COMORBIDITY; DATABASES, PHARMACEUTICAL; FEMALE; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; LUNG DISEASES; MALE; MEDICATION ADHERENCE; MESALAMINE; MIDDLE AGED; PATIENT COMPLIANCE; QUEBEC; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 84873027223     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-13-23     Document Type: Article

References (33)

1. Logan I, Bowlus CL. The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 2010, 9(5):A372-378. 10.1016/j.autrev.2009.11.008, 19903540.
2. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down?. World J Gastroenterol 2006, 12(38):6102-6108.
3. Hawthorne AB, Stenson R, Gillespie D, Swarbrick ET, Dhar A, Kapur KC, Hood K, Probert CS. One-year investigator-blind randomized multicenter trial comparing asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflamm Bowel Dis 2012, 18(10):1885-1893. 10.1002/ibd.21938, 22081522.
4. Loftus CG, Loftus EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ, Sandborn WJ. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007, 13(3):254-261. 10.1002/ibd.20029, 17206702.
5. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004, 53(10):1471-1478. 10.1136/gut.2004.041616, 1774248, 15361497.
6. Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther 2010, 31(7):693-707. 10.1111/j.1365-2036.2010.04234.x, 20064142.
7. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009, 361(21):2066-2078. 10.1056/NEJMra0804647, 3491806, 19923578.
8. Holtmann MH, Galle PR. Current concept of pathophysiological understanding and natural course of ulcerative colitis. Langenbecks Arch Surg 2004, 389(5):341-349. 10.1007/s00423-003-0448-5, 14760536.
9. Stange EF. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008, 2(1):1-23.
10. Danese S, Fiocchi C. Ulcerative colitis. N Eng J Med 2011, 365(18):1713-1725.
11. Lakatos PL. Environmental factors affecting inflammatory bowel disease: have we made progress?. Dig Dis 2009, 27(3):215-225. 10.1159/000228553, 19786744.
12. Lakatos PL, Fischer S, Lakatos L, Gal I, Papp J. Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take "toll" ?. World J Gastroenterol 2006, 12(12):1829-1841.
13. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010, 105(3):501-523. quiz 524, 10.1038/ajg.2009.727, 20068560.
14. Letter TM. Drugs for inflammatory bowel disease. Treatment Guidelines 2009, New York: The Medical Letter, 7.
15. Régie de l'assurance maladie du Québec Liste de médicaments 2009, Régie de l'assurance maladie du Québec, 3540685, 23320167, Régie de l'assurance maladie du Québec.
16. Lakatos PL, Lakatos L. Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet?. Pharmacol Res 2008, 58(3-4):190-195.
17. Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 2010, 138(4):1286-1296. 1296 e1281-1283, 10.1053/j.gastro.2009.12.054, 20064514.
18. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006, 23(5):577-585. 10.1111/j.1365-2036.2006.02809.x, 16480396.
19. Hawthorne AB, Rubin G, Ghosh S. Review article: medication non-adherence in ulcerative colitis-strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 2008, 27(12):1157-1166. 10.1111/j.1365-2036.2008.03698.x, 18384664.
20. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992, 45(2):197-203. 10.1016/0895-4356(92)90016-G, 1573438.
21. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007, 10(1):3-12. 10.1111/j.1524-4733.2006.00139.x, 17261111.
22. Carter CT, Leher H, Smith P, Smith DB, Waters HC. Impact of persistence with infliximab on hospitalizations in ulcerative colitis. Am J Manag Care 2011, 17(6):385-392.
23. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001, 96(10):2929-2933. 10.1111/j.1572-0241.2001.04683.x, 11693328.
24. Levy RL, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimens. Am J Gastroenterol 1999, 94(7):1733-1742. 10.1111/j.1572-0241.1999.01200.x, 10406229.
25. Jackson CA, Clatworthy J, Robinson A, Horne R. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol 2010, 105(3):525-539. 10.1038/ajg.2009.685, 19997092.
26. Cerveny P, Bortlik M, Kubena A, Vlcek J, Lakatos PL, Lukas M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 2007, 13(10):1244-1249. 10.1002/ibd.20189, 17538983.
27. Kane SV, Accortt NA, Magowan S, Brixner D. Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther 2009, 29(8):855-862. 10.1111/j.1365-2036.2009.03941.x, 19183154.
28. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003, 114(1):39-43. 10.1016/S0002-9343(02)01383-9, 12543288.
29. Ediger JP, Walker JR, Graff L, Lix L, Clara I, Rawsthorne P, Rogala L, Miller N, McPhail C, Deering K, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007, 102(7):1417-1426. 10.1111/j.1572-0241.2007.01212.x, 17437505.
30. Zhu B, Zhao Z, McCollam P, Anderson J, Bae JP, Fu H, Zettler M, Lenarz L. Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Curr Med Res Opin 2011, 27(3):633-641. 10.1185/03007995.2010.551657, 21241206.
31. Liu X, Chen Y, Faries DE. Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder. Clinico econ Outcomes Res 2011, 3:63-72.
32. Farup PG, Hinterleitner TA, Lukas M, Hebuterne X, Rachmilewitz D, Campieri M, Meier R, Keller R, Rathbone B, Oddsson E. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis 2001, 7(3):237-242. 10.1097/00054725-200108000-00009, 11515850.
33. The Mesalamine Study Group An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. Ann Intern Med 1996, 124:204-211. The Mesalamine Study Group.